Nigeria is poised to become a hub for Active Pharmaceutical Ingredients (API) manufacturing by early 2024, thanks to a private-sector initiative supported by the European Investment Bank. Emzor Pharmaceutical Industries Limited secured a €13.85 million EIB loan to develop a $23 million plant, which is nearing completion. The project will initially focus on four anti-malaria APIs, with plans to expand into three more areas. This development is crucial for Nigeria, which currently imports over 90% of its APIs. Producing APIs locally will reduce costs and enhance the competitiveness of Nigerian drug manufacturers.
Key Points:
- Emzor Pharmaceutical Industries Limited secured a €13.85 million EIB loan to develop a $23 million API manufacturing plant, expected to be operational by February 2024.
- Initially focusing on four anti-malaria APIs, the plant plans to expand into three more areas, generating over 500 jobs.
- The project addresses Nigeria’s heavy reliance on imported APIs, a critical shortfall in the drug production process.
- Producing APIs locally will reduce costs and enhance the competitiveness of Nigerian drug manufacturers against imports from India and China.
- The value of finished imported drugs like artemether/lumefantrine and sulfadoxine/pyrimethamine has been increasing, highlighting the significance of local API production.
Analysis: Nigeria’s move towards becoming a hub for pharmaceutical manufacturing, particularly in API production, is a significant step towards achieving drug security and reducing dependency on imports. This initiative not only addresses a critical shortfall in the pharmaceutical sector but also creates a competitive advantage for local manufacturers. Additionally, producing APIs locally will contribute to job creation and economic growth. As the project advances, it will be essential to maintain high-quality standards and ensure that prices remain competitive with global counterparts. The success of this endeavor could serve as a model for other African countries seeking to bolster their pharmaceutical industries.
